A Phase 1 interventional study of Saxagliptin/Metformin in Diabetes, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-23.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 1, and was the 7th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 66 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 68th largest by enrollment of the 91 interventional ones that give a count, is one of 3 that started in 2013, is one of 20 in phase 1, and was the 96th registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if tablets manufactured at different sites have the same bioavailability, that is yield similar blood levels/concentrations of the drugs and are handled by the body similarly
Primary Purpose:
Other: Protocol designed to demonstrate the bioequivalence of the fixed dose combination of 5 mg Saxagliptin and 1000 mg Metformin Extended Release Tablet manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico relative to the fixed dose combination tablet manufactured in Mt. Vernon, Indiana and the bioequivalence of the fixed dose combination of 5 mg Saxagliptin and 500 mg Metformin Extended Release Tablet manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico relative to the fixed dose combination tablet manufactured in Mt. Vernon, Indiana in healthy human subjects under fed conditions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
Drug: Saxagliptin/Metformin
Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
Drug: Saxagliptin/Metformin
Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
Drug: Saxagliptin/Metformin
Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
Drug: Saxagliptin/Metformin
Drug pages: Saxagliptin · Metformin
Also known as: Kombiglyze XR
Point estimates and 90% CIs for the ratio of geometric means for Cmax for Saxagliptin and Metformin in the 5/1000 mg FDC XR (Mt.Vernon/Humacao) and 5/1000 mg FDC XR (Mt. Vernon)
Cmax=Maximum observed plasma concentration CI=Confidence interval FDC=Fixed dosed combination XR=Extended release
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Point estimates and 90% CIs for the ratio of geometric means for AUC(0-T) for Saxagliptin and Metformin in the 5/1000 mg FDC XR (Mt.Vernon/Humacao) and 5/1000 mg FDC XR (Mt. Vernon)
AUC(0-T)=Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/1000 mg FDC XR (Mt.Vernon/Humacao) and 5/1000 mg FDC XR (Mt. Vernon)
AUC(INF)=Area under the plasma concentration-time curve from time zero extrapolated to infinity
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Point estimates and 90% CIs for the ratio of geometric means for Cmax for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Point estimates and 90% CIs for the ratio of geometric means for AUC(0-T) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Time to maximum observed plasma concentration (Tmax) for Saxagliptin and Metformin and for 5-OH Saxagliptin (Treatments A, B, C, and D)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Terminal half life (T-HALF) for Saxagliptin and Metformin and for 5-OH Saxagliptin (Treatments A, B, C, and D)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Cmax for 5-OH Saxagliptin (Treatments A, B, C, and D)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
AUC(0-T) for 5-OH Saxagliptin (Treatments A, B, C, and D)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
AUC(INF) for 5-OH Saxagliptin (Treatments A, B, C, and D)
Time frame: 19 time points up to Day 3 of Periods 1 and 2
Safety assessments based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests
Parameters will include: 1. Serious adverse events 2. Deaths 3. Adverse events leading to discontinuation 4. Number of subjects with potentially clinically significant changes in vital signs, electrocardiograms (ECGs) or safety laboratory findings defined as meeting marked abnormality criteria
Time frame: Up to Day 3 of Periods 1 and 2 and up to 30 days post discontinuation of dosing
The record gives a start of Jun 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin